Cardioprotective Anesthesia in a Sulfonylurea-Treated Redo CABG
A 68-year-old man on long-term glyburide is scheduled for a redo coronary artery bypass. The argument for volatile anesthesia's own cardioprotective mechanism runs straight into a drug already sitting in his system that may have switched that mechanism off years before he ever reached the operating room.
Walter G., a 68-year-old man, has run the same hardware store since his father handed it to him thirty years ago, and still climbs the stockroom ladder most mornings despite two grafts placed a decade ago that have finally started failing. Type 2 diabetes has been part of his history for eighteen years, managed for most of that time on glyburide 10mg daily after metformin alone stopped holding his A1c below 8. His A1c today is 7.6% — adequate control, and more to the point, evidence the glyburide is still doing real pharmacologic work rather than sitting on his list as a prescription nobody has revisited. Recurrent angina over the past two months, now provoked by walking the length of his own store, brought him back to cardiology, and catheterization showed a patent left internal mammary graft but two new, severe stenoses in previously ungrafted vessels — disease that has moved on from where the original surgery left off, not a failure of the earlier grafts themselves.
A redo sternotomy carries real, well-documented added risk over a first-time CABG: denser adhesions, longer time to establish bypass, and a cross-clamp period that will likely run longer than his first operation's. That added ischemic exposure is exactly the setting in which anesthetic choice has been argued to matter — volatile agents open mitochondrial KATP channels through a pathway that mimics the heart's own ischemic preconditioning response. MYRIAD, the largest trial ever built to test that idea against a hard outcome, randomized 5,400 cardiac surgery patients to volatile maintenance or total intravenous anesthesia and found no difference in one-year mortality: 2.8% against 3.0%. Walter sits squarely inside the population MYRIAD enrolled, which means its null result is not something his case escapes on a technicality. What complicates the mechanism further, and is specific to him rather than to the trial, is the glyburide already circulating in his system: sulfonylureas bind the same SUR receptor subunits the KATP channel is assembled from, and the question the team is working through is whether that channel is even available to a volatile anesthetic by the time he reaches the OR.
Choosing the maintenance agent before the second sternotomy
I want sevoflurane running through the whole case, not just as a convenience drug. His cross-clamp time is going to run longer than his first surgery's — redo sternotomies almost always do — and that's exactly the added ischemic exposure where anesthetic preconditioning, if it's doing anything at all, should earn its keep.
The mechanism you're describing is real — mitochondrial KATP channel opening genuinely mimics ischemic preconditioning, and I'm not disputing that biology. But MYRIAD, the largest trial that ever actually tested it against a hard outcome, randomized over five thousand cardiac surgery patients to volatile versus TIVA and found no significant difference in one-year all-cause mortality. The mechanism didn't translate at scale.
And separate from MYRIAD's overall result, I don't think the mechanism is even available to Walter specifically. Glyburide binds the SUR1/SUR2 receptor subunits KATP channels are built from — the same target volatile anesthetics act through. Older mechanistic work in sulfonylurea-treated diabetics found that chronic sulfonylurea therapy blocks both ischemic and anesthetic preconditioning outright. You're arguing for a mechanism that may already be pharmacologically switched off in this patient before he ever reaches the OR.
That's a fair point, and it changes my reasoning even if it doesn't change my recommendation much — you're right that if the receptor is already occupied, I can't honestly claim I'm giving him a preconditioning benefit MYRIAD couldn't even prove existed for the general population. I'll concede the mechanistic argument doesn't hold up for him specifically.
Where I still land on sevoflurane is more mundane: hemodynamic predictability through a longer, more adhesion-heavy dissection, and a volatile agent I can titrate against depth of anesthesia monitoring without the accumulation concerns a long TIVA infusion can raise in a case that may run past six hours. Not the argument I opened with, but a real one.
Agreed: sevoflurane maintenance, glyburide held preoperatively with an insulin infusion for glycemic control through the case, standard cardiac monitoring with norepinephrine staged for post-bypass weaning.
Not agreed: whether the sulfonylurea-preconditioning-blockade literature should change maintenance-agent selection as a matter of routine practice for every diabetic patient on a sulfonylurea, or whether it's a mechanistic footnote that shouldn't drive the decision once MYRIAD already found no mortality difference at the population level. The team's own final choice ended up resting on a different, unrelated rationale than either opening position, which both voices noted without treating it as resolving the larger question either way.